Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 877 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endocrine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Two Internet Supported Natural Family Planning Methods

NCT00843336
View directory record Official record
Conditions
Pregnancy
Interventions
Electronic hormonal fertility monitoring, Self-monitoring
Behavioral
Lead sponsor
Marquette University
Other
Eligibility
18 Years to 42 Years
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Nov 4, 2026, 10:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 4, 2026, 10:38 AM EST
Completed Not applicable Interventional Results available

Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.

NCT02904512
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose, Point of Care (POC) blood glucose
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Nov 4, 2026, 10:38 AM EST
Completed No phase listed Observational Results available

Pilot Study Assessing Oxidative Stress in Children

NCT01052207
View directory record Official record
Conditions
Adrenal Insufficiency, Critical Illness
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Nov 4, 2026, 10:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Comparing the Effects of Exercise on the Structure and Function of Fat Tissue

NCT05328570
View directory record Official record
Conditions
Adiposity
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Nov 4, 2026, 10:38 AM EST
Completed Phase 4 Interventional Results available

Vitamin D Repletion in Primary Hyperparathyroidism

NCT01306656
View directory record Official record
Conditions
Primary Hyperparathyroidism, Vitamin D Deficiency
Interventions
10,000 IU Vitamin D3, Placebo, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Nov 4, 2026, 10:38 AM EST
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Investigating Biological Markers, Targets, and Intervention for Mood Disorders

NCT04632498
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Stress
Interventions
Mindfulness Based Intervention
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 4, 2026, 10:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Blood Glycan Biomarkers in Women With Stage IV Breast Cancer

NCT00897962
View directory record Official record
Conditions
Breast Cancer
Interventions
Healthy Controls, Metastatic Breast Cancer, Non-cancer medical illness
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Nov 4, 2026, 10:38 AM EST
Completed No phase listed Observational

Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)

NCT06830486
View directory record Official record
Conditions
Breast Cancer
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

7 Day Continuous Parathyroid Hormone IV Infusion

NCT00377312
View directory record Official record
Conditions
Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
Interventions
Parathyroid Hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Nov 4, 2026, 10:38 AM EST
Active, not recruiting No phase listed Observational

Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy

NCT05863676
View directory record Official record
Conditions
Gender Dysphoria, Transgender
Interventions
Oophorectomy, Infectious Disease Testing
Procedure · Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
9 Years and older · Female only
Enrollment
20 participants
Timeline
2020 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340
View directory record Official record
Conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
55
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Completed Phase 1 Interventional

Study of 68Ga-R10602

NCT06745804
View directory record Official record
Conditions
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Interventions
68Ga-R10602 injection
Drug
Lead sponsor
Radionetics Oncology
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging Biomarkers of Pancreatic Function and Disease

NCT05659147
View directory record Official record
Conditions
Pancreatitis, Diabetes Mellitus
Interventions
Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin
Diagnostic Test · Genetic · Other + 1 more
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Recruiting Phase 1Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen
Drug · Combination Product · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Completed No phase listed Observational

Exogenous Sex Hormones and PONV

NCT06816355
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Sex Hormone, Transgender
Interventions
Orchiectomy, Hysterectomy, Augmentation mammoplasty
Procedure
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
7,348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Nov 4, 2026, 10:38 AM EST
Terminated Phase 2 Interventional Results available

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

NCT00225758
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib
Drug
Lead sponsor
Gary Schwartz
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Aurora, Colorado • Lebanon, New Hampshire • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Nov 4, 2026, 10:38 AM EST
Recruiting Early Phase 1 Interventional

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

NCT04174352
View directory record Official record
Conditions
ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions
Tamoxifen, FES PET/CT
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Completed Not applicable Interventional Results available

Lifestyle, Exercise, and Nutrition Study Early After Diagnosis

NCT03314688
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Dietary/Physical Activity intervention, Usual Care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Not listed No phase listed Observational

Continuous Monitoring and Control of Hypoglycemia

NCT03340831
View directory record Official record
Conditions
Diabetes
Interventions
Continuous Glucose Monitoring (CGM)
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
2 Years and older
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
25
States / cities
La Jolla, California • La Mesa, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Nov 4, 2026, 10:38 AM EST
Completed Phase 3 Interventional

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

NCT00002881
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Nov 4, 2026, 10:38 AM EST
Active, not recruiting Phase 2 Interventional Results available

Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
View directory record Official record
Conditions
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 4, 2026, 10:38 AM EST
Recruiting No phase listed Observational

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

NCT04615988
View directory record Official record
Conditions
Thyroid, PD-1, Cancer
Interventions
blood draw and questionnaire completion, questionnaire completion, blood collection
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 4, 2026, 10:38 AM EST